<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05097599</url>
  </required_header>
  <id_info>
    <org_study_id>STR-004-001</org_study_id>
    <nct_id>NCT05097599</nct_id>
  </id_info>
  <brief_title>Strata PATH™ (Precision Indications for Approved Therapies)</brief_title>
  <acronym>Strata PATH</acronym>
  <official_title>Strata PATH (Precision Indications for Approved Therapies): A Study Evaluating the Clinical Activity and Safety of Approved Drugs Within Biomarker-Guided Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Strata Oncology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Strata Oncology</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      StrataPATH is a non-randomized, open-label trial designed to explore efficacy and safety of&#xD;
      multiple FDA-approved and commercially available cancer therapies in new, biomarker-guided&#xD;
      patient populations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      StrataPATH is a non-randomized, open-label trial designed to explore efficacy and safety of&#xD;
      multiple FDA-approved and commercially available cancer therapies in new, biomarker-guided&#xD;
      patient populations. Aiming to increase clinical benefit for patients, this study will&#xD;
      leverage technology advancements, scientific literature, and Strata's real-world evidence to&#xD;
      define novel, highly responsive pan-tumor molecular indications for FDA-approved therapies in&#xD;
      both the advanced and micro-metastatic settings. Strata will rapidly identify participants&#xD;
      who have efficacy signals for possible expansion into adaptive or randomized studies.&#xD;
      Enrollment in each drug/biomarker cohort is competitive. Cohorts may be added, changed, or&#xD;
      discontinued over the course of the study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 21, 2021</start_date>
  <completion_date type="Anticipated">October 21, 2029</completion_date>
  <primary_completion_date type="Anticipated">October 21, 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR) defined as the percentage of participants with a best overall response of CR or PR based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, as assessed by the investigator</measure>
    <time_frame>Assessed throughout end of study, up to 5 years</time_frame>
    <description>RECIST criteria will be used to assess the clinical activity of anti-cancer therapies in participants with pre-specified biomarker profiles.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ctDNA response: The proportion of participants with a &lt;50% ratio of mean variant allele frequency (VAF) will be defined as ctDNA responders.</measure>
    <time_frame>6 months</time_frame>
    <description>Molecular response calculated as a ratio of mean VAF on treatment at 6 months compared to baseline VAF will be used to assess the clinical activity of anti-cancer therapies in participants with pre-specified biomarker profiles.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR) defined as the time from first documentation of disease response (CR or PR) until first documentation of progressive disease</measure>
    <time_frame>Assessed throughout end of study, up to 5 years</time_frame>
    <description>DoR will be used to assess the duration of response in anti-cancer therapies in participants with pre-specified biomarker profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Discontinuation (TTD) defined as length of time from the date the participant initiates the systemic treatment to the date the participant discontinues treatment as compared to prior TTD from prior anticancer therapy</measure>
    <time_frame>Assessed throughout end of study, up to 5 years</time_frame>
    <description>TTD will be used to assess the duration of response in anti-cancer therapies in participants with pre-specified biomarker profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTnT (Time to Next Treatment) defined as the length of time from the date the participant initiates study treatment to the date the participant initiates their next systemic treatment or death.</measure>
    <time_frame>Assessed throughout end of study, up to 5 years</time_frame>
    <description>TTnT will be used to assess the duration of response in anti-cancer therapies in participants with pre-specified biomarker profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ctDNA Response Rate</measure>
    <time_frame>Assessed throughout end of study, up to 5 years</time_frame>
    <description>Evaluate ctDNA response rate at additional timepoints for participants who received anti-cancer therapies with pre-specified biomarker profiles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Assessed throughout end of study, up to 5 years</time_frame>
    <description>Evaluate overall survival (OS) for participants who received an anticancer therapy with pre-specified biomarker profiles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events (SAEs)</measure>
    <time_frame>Assessed throughout end of study, up to 5 years</time_frame>
    <description>Monitor and summarize any unexpected safety events in participants who received an anticancer biomarker-guided therapy</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Explore the correlation between serial ctDNA levels over time and participant response to therapy based on RECIST 1.1, as assessed by the investigator.</measure>
    <time_frame>Assessed throughout end of study, up to 5 years</time_frame>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Cancer</condition>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Lorbrena® (Lorlatinib)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Braftovi® (Encorafenib) + Mektovi® (Binimetinib)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Talzenna® (Talazoparib)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Enhertu® (fam-trastuzumab deruxtecan-nxki)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Padcev® (Enfortumab-vedotin)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorlatinib</intervention_name>
    <description>This arm of the Strata PATH trial will assess the clinical benefit of lorlatinib in ALK and ROS1 gene fusion positive solid tumors with the exception of NSCLC.</description>
    <arm_group_label>Lorbrena® (Lorlatinib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Encorafenib + Binimetinib</intervention_name>
    <description>This arm of the Strata PATH trial will assess the clinical benefit of encorafenib plus binimetinib in BRAF p.v600X mutated solid tumors with the exception of melanoma and colorectal cancer.</description>
    <arm_group_label>Braftovi® (Encorafenib) + Mektovi® (Binimetinib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talazoparib</intervention_name>
    <description>This arm of the Strata PATH trial will assess the clinical benefit of talazoparib in patients with advanced solid tumors harboring deep deletions or deleterious mutations with LOH in BRCA1/2 and PALB2, excluding HER2 negative breast cancer.</description>
    <arm_group_label>Talzenna® (Talazoparib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enhertu</intervention_name>
    <description>This arm of the Strata PATH trial will assess the clinical benefit of Enhertu in patients with advanced solid tumors harboring HER2 over-expression as detected by StrataEXP.</description>
    <arm_group_label>Enhertu® (fam-trastuzumab deruxtecan-nxki)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PADCEV</intervention_name>
    <description>This arm of the StrataPATH trial will assess the clinical benefit of enfortumab in patients with advanced solid tumors harboring Nectin-4 over-expression as detected by StrataEXP.</description>
    <arm_group_label>Padcev® (Enfortumab-vedotin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        To be eligible to participate in this study, an individual must meet each of the criterion&#xD;
        below and the criteria indicated in the selected biomarker/drug cohort appendix:&#xD;
&#xD;
          1. Male or female ≥18 years of age.&#xD;
&#xD;
          2. Pathologically confirmed solid tumor&#xD;
&#xD;
          3. Participants must be able to follow study visit schedule and willing to provide up to&#xD;
             20 mL of peripheral blood samples at the indicated time points&#xD;
&#xD;
          4. Leftover formalin-fixed, paraffin-embedded (FFPE) tumor tissue or historical CGP or&#xD;
             RNA profiling test results available for submission&#xD;
&#xD;
          5. Biomarker positive for the defined cohort&#xD;
&#xD;
          6. For individuals with treated or stable brain metastases: No evidence of progression&#xD;
             for at least 4 weeks prior to consent&#xD;
&#xD;
          7. Adequate bone marrow, organ function &amp; laboratory parameters as determined by the&#xD;
             treating physician&#xD;
&#xD;
          8. Adequate cardiac function: 8.1) Left ventricular ejection fraction (LVEF) ≥ 50%, 8.2)&#xD;
             QTc interval ≤ 470 ms (females) or ≤ 450 ms (males) average preferred&#xD;
&#xD;
        An individual who meets any of the following criteria will be excluded from participation&#xD;
        in this study:&#xD;
&#xD;
          1. Receiving another anticancer therapy&#xD;
&#xD;
          2. Major surgery within 4 weeks prior to study entry&#xD;
&#xD;
          3. Has received a systemic anticancer therapy within 3 weeks of first study dose&#xD;
&#xD;
          4. Females who are pregnant or nursing or plan to become pregnant or anyone unwilling to&#xD;
             use contraception for the duration of treatment&#xD;
&#xD;
          5. Ongoing toxicity of CTCAE grade ≥2, other than peripheral neuropathy, related to&#xD;
             anticancer therapy that was completed within 4 weeks of consent&#xD;
&#xD;
          6. Ongoing peripheral neuropathy of CTCAE grade ≥3&#xD;
&#xD;
          7. History of stroke including transient ischemic attack (TIA) or acute myocardial&#xD;
             infarction within 6 months of consent&#xD;
&#xD;
          8. Participant has a known history of human immunodeficiency virus (HIV), Hepatitis B or&#xD;
             known active Hepatitis C virus infection&#xD;
&#xD;
          9. Medical condition that would place the patient at risk as a result of blood donation,&#xD;
             such as bleeding disorder&#xD;
&#xD;
         10. Any other clinically significant medical condition that, in the opinion of the&#xD;
             treating physician, makes participation undesirable, including but not limited to&#xD;
             ongoing or active infection, significant uncontrolled hypertension, or severe&#xD;
             psychiatric illness.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kat Kwiatkowski, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Strata Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ida Cao</last_name>
    <phone>(734) 527-1000</phone>
    <email>ida.cao@strataoncology.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephannie Perrin</last_name>
    <phone>(734) 527-1000</phone>
    <email>stephannie.perrin@strataoncology.com</email>
  </overall_contact_backup>
  <link>
    <url>https://cancerstatisticscenter.cancer.org/#/.</url>
    <description>Society, A.C. Cancer Statistics Center. 2020 9/4/2020</description>
  </link>
  <link>
    <url>https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication</url>
    <description>Administration, U.F.a.D., FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. 2017.</description>
  </link>
  <link>
    <url>https://www.merck.com/news/mercks-keytruda-pembrolizumab-demonstrated-superior-disease-free-survival-dfs-compared-with-placebo-as-adjuvant-therapy-in-patients-with-renal-cell-carcinoma-rcc-following-surgery/</url>
    <description>Merck, Merck's KEYTRUDA® (pembrolizumab) Demonstrated Superior Disease-Free Survival (DFS) Compared With Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma (RCC) Following Surgery, in Press Release. 2021.</description>
  </link>
  <link>
    <url>http://scholar.google.com/scholar_lookup?&amp;title=Clinical%20Measurement%20in%20Drug%20Evaluation&amp;pages=3-22&amp;publication_year=1995&amp;author=Temple%2CRJ</url>
    <description>Temple, R., A regualtory authority's opinion about surrogate endpoints, in Clinical Measurement in Drug Evaluation, W.T. Nimmo, Editor. 1995, J.Wiley: New York.</description>
  </link>
  <link>
    <url>https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approval-cancer-drugs-and-biologics</url>
    <description>Administration, U.F.a.D., Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics Guidance for Industry. 2018.</description>
  </link>
  <link>
    <url>https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions</url>
    <description>Administration, U.F.a.D., FDA approves larotrectinib for solid tumors with NTRK gene fusions. 2018.</description>
  </link>
  <reference>
    <citation>Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL, Siegel RL. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019 Sep;69(5):363-385. doi: 10.3322/caac.21565. Epub 2019 Jun 11.</citation>
    <PMID>31184787</PMID>
  </reference>
  <reference>
    <citation>Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, Wong F, Azad NS, Rucki AA, Laheru D, Donehower R, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Greten TF, Duffy AG, Ciombor KK, Eyring AD, Lam BH, Joe A, Kang SP, Holdhoff M, Danilova L, Cope L, Meyer C, Zhou S, Goldberg RM, Armstrong DK, Bever KM, Fader AN, Taube J, Housseau F, Spetzler D, Xiao N, Pardoll DM, Papadopoulos N, Kinzler KW, Eshleman JR, Vogelstein B, Anders RA, Diaz LA Jr. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017 Jul 28;357(6349):409-413. doi: 10.1126/science.aan6733. Epub 2017 Jun 8.</citation>
    <PMID>28596308</PMID>
  </reference>
  <reference>
    <citation>Ramalingam SS, Yang JC, Lee CK, Kurata T, Kim DW, John T, Nogami N, Ohe Y, Mann H, Rukazenkov Y, Ghiorghiu S, Stetson D, Markovets A, Barrett JC, Thress KS, Jänne PA. Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 Mar 20;36(9):841-849. doi: 10.1200/JCO.2017.74.7576. Epub 2017 Aug 25.</citation>
    <PMID>28841389</PMID>
  </reference>
  <reference>
    <citation>Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L; KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015 May 21;372(21):2018-28. doi: 10.1056/NEJMoa1501824. Epub 2015 Apr 19.</citation>
    <PMID>25891174</PMID>
  </reference>
  <reference>
    <citation>Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Maio M, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan P, Ibrahim N, Marreaud S, van Akkooi ACJ, Suciu S, Robert C. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med. 2018 May 10;378(19):1789-1801. doi: 10.1056/NEJMoa1802357. Epub 2018 Apr 15.</citation>
    <PMID>29658430</PMID>
  </reference>
  <reference>
    <citation>Khozin S, Miksad RA, Adami J, Boyd M, Brown NR, Gossai A, Kaganman I, Kuk D, Rockland JM, Pazdur R, Torres AZ, Zhi J, Abernethy AP. Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer. Cancer. 2019 Nov 15;125(22):4019-4032. doi: 10.1002/cncr.32383. Epub 2019 Aug 5.</citation>
    <PMID>31381142</PMID>
  </reference>
  <reference>
    <citation>Blumenthal GM, Gong Y, Kehl K, Mishra-Kalyani P, Goldberg KB, Khozin S, Kluetz PG, Oxnard GR, Pazdur R. Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer. Ann Oncol. 2019 May 1;30(5):830-838. doi: 10.1093/annonc/mdz060.</citation>
    <PMID>30796424</PMID>
  </reference>
  <reference>
    <citation>Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989 Apr;8(4):431-40.</citation>
    <PMID>2727467</PMID>
  </reference>
  <reference>
    <citation>Fleming TR, Powers JH. Biomarkers and surrogate endpoints in clinical trials. Stat Med. 2012 Nov 10;31(25):2973-84. doi: 10.1002/sim.5403. Epub 2012 Jun 18.</citation>
    <PMID>22711298</PMID>
  </reference>
  <reference>
    <citation>Thompson JC, Carpenter EL, Silva BA, Rosenstein J, Chien AL, Quinn K, Espenschied CR, Mak A, Kiedrowski LA, Lefterova M, Nagy RJ, Katz SI, Yee SS, Black TA, Singh AP, Ciunci CA, Bauml JM, Cohen RB, Langer CJ, Aggarwal C. Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy. JCO Precis Oncol. 2021 Mar 19;5. pii: PO.20.00321. doi: 10.1200/PO.20.00321. eCollection 2021.</citation>
    <PMID>34095713</PMID>
  </reference>
  <reference>
    <citation>Zhang Q, Luo J, Wu S, Si H, Gao C, Xu W, Abdullah SE, Higgs BW, Dennis PA, van der Heijden MS, Segal NH, Chaft JE, Hembrough T, Barrett JC, Hellmann MD. Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. Cancer Discov. 2020 Dec;10(12):1842-1853. doi: 10.1158/2159-8290.CD-20-0047. Epub 2020 Aug 14.</citation>
    <PMID>32816849</PMID>
  </reference>
  <reference>
    <citation>Jung SH, Lee T, Kim K, George SL. Admissible two-stage designs for phase II cancer clinical trials. Stat Med. 2004 Feb 28;23(4):561-9.</citation>
    <PMID>14755389</PMID>
  </reference>
  <reference>
    <citation>Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989 Mar;10(1):1-10.</citation>
    <PMID>2702835</PMID>
  </reference>
  <reference>
    <citation>Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19.</citation>
    <PMID>32955177</PMID>
  </reference>
  <reference>
    <citation>Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.</citation>
    <PMID>19097774</PMID>
  </reference>
  <reference>
    <citation>Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EGE; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017 Mar;18(3):e143-e152. doi: 10.1016/S1470-2045(17)30074-8. Epub 2017 Mar 2. Review. Erratum in: Lancet Oncol. 2019 May;20(5):e242.</citation>
    <PMID>28271869</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 1, 2021</study_first_submitted>
  <study_first_submitted_qc>October 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Advanced Solid Tumor</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Talazoparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

